The relevance of optimised incretin therapies extends beyond their action on blood glucose regulation and control of body weight, with GLP-1RAs providing beneficial effects for blood pressure disorders (Martins et al., 2020) and neurodegenerative conditions including Alzheimer’s (Bomfim et al., 2012) and Parkinson’s disease (de Pablo-Fernandez et al., 2018). This evidence concerns the gene GCG and Parkinson disease.